Psoriasis Clinical Trial

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Summary

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have been diagnosed with plaque psoriasis by a dermatologist
Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion Criteria:

Currently participating in an interventional clinical trial (does not include observational registry or study)

Study is for people with:

Psoriasis

Estimated Enrollment:

1500

Study ID:

NCT05744466

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Local Institution
Waltham Massachusetts, 02451, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Estimated Enrollment:

1500

Study ID:

NCT05744466

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.